Bausch's Ortho Dermatologics: Studies Demonstrate Efficacy of Plaque Psoriasis Drug
October 02 2018 - 08:50AM
Dow Jones News
By Michael Dabaie
Bausch Health Cos. Inc.'s (BHC) Ortho Dermatologics said Tuesday
that in two Phase 3 randomized controlled trials Bryhali Lotion was
consistently more effective than vehicle in achieving treatment
success for moderate-to-severe plaque psoriasis.
Bryhali Lotion is an investigational potent to superpotent
corticosteroid. By week eight, 36.5% in Study 1 and 38.4% in Study
2 of Bryhali patients had achieved treatment success, compared to
8.1% and 12% of patients receiving vehicle. At four weeks post
treatment, no rebound of symptoms was observed in patients using
Bryhali Lotion, the company said. The results were published in the
Journal of Drugs in Dermatology.
The company said Bryhali Lotion was also found to be
well-tolerated, with a similar number of patients in the Bryhali
Lotion and vehicle groups reporting adverse events.
Bausch shares were down 0.2% premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 02, 2018 08:35 ET (12:35 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Bausch Health Companies (NYSE:BHC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bausch Health Companies (NYSE:BHC)
Historical Stock Chart
From Mar 2023 to Mar 2024